Search
Close this search box.
Search
Subscriber Log In
Webinar | On demand

World Preview 2024: Pharma’s Growth Boost

Are you ready to look at the pharma landscape through a long-range lens? Evaluate has released new forecasts out to 2030. With obesity, immuno-inflammation and oncology driving an increase in CAGR to 2030 of 7.7%, the panel will discuss what this means for the 10 top-selling therapies and the domination of the so-called ‘big drugs for big diseases’.

Watch the webinar.








What to Expect

  • Novo and Lilly soar up the company charts, having just entered the top 10 last year.
  • Resurgent CNS and respiratory are both prominent among most valuable pipeline candidates.
  • The prescription drug market will hit $1.7 trillion.

Melanie Senior

Author, World Preview

Evaluate-Author-Daniel-Chancellor

Dan Chancellor

VP Norstella Thought Leadership

Evaluate-Author-Paul-Verdin

Paul Verdin

SVP, Consulting & Analytics, Evaluate